Core Insights - Upstream Bio, Inc. is set to present new analyses from the Phase 2 VIBRANT trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) at the AAAAI Congress 2026 [1][2] - Verekitug is a novel monoclonal antibody targeting the TSLP receptor, which plays a significant role in inflammatory responses [3][4] - The company is advancing verekitug through multiple Phase 2 clinical trials for various inflammatory diseases, including CRSwNP, severe asthma, and chronic obstructive pulmonary disease (COPD) [5][6] Presentation Details - The presentation titled "Efficacy and Safety of Verekitug (UPB-101) in Chronic Rhinosinusitis with Nasal Polyps: Results of the Phase 2 VIBRANT Trial" will be delivered by Dr. Joseph Han [2] - Scheduled for March 1, 2026, from 9:45 am to 10:45 am EST at the Convention Center, Level 2, Hall E [2] About Verekitug - Verekitug is the only known antagonist in clinical development that targets the TSLP receptor, inhibiting proinflammatory signaling [3][6] - TSLP is a key cytokine in allergic and inflammatory diseases, making it a strategic target for therapeutic intervention [4][6] Company Overview - Upstream Bio focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders [6] - The company aims to address unmet medical needs with its innovative monoclonal antibody, verekitug, which is currently in various stages of clinical trials [6]
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026